Our Services
Medical Information
Helpful Resources
Published on: 10/22/2026
Combined estrogen-containing pills, patches, and rings raise clot risk, so guidance often calls for stopping them about four weeks before major surgery or any procedure with prolonged immobilization, while progestin-only pills, implants, and hormonal IUDs are usually continued. Whether you stop depends on the type of surgery, your personal and family clot history, smoking, weight, and whether reliable backup contraception is in place, since stopping without a plan creates pregnancy risk. Minor procedures under local anesthetic with quick recovery typically require no change at all, and some surgeons prefer continuing the pill while using preventive blood thinners or compression instead. These distinctions matter, and the details below explain what gets stopped, when to restart afterward, and the warning signs of leg swelling, chest pain, or breathlessness that need urgent care. If you are weighing an upcoming operation, unexplained leg or chest symptoms, or confusion about your own hormone method, a free, instant, online symptom check can help you organize what you are experiencing and clarify which questions to raise with your surgeon or prescriber next.
Last reviewed for medical accuracy: 10/22/2026
Undergoing surgery while taking a hormonal birth control pill can raise questions about clot risk and safety. You may have heard that estrogen-containing birth control slows blood flow, increasing the risk of a dangerous clot (venous thromboembolism, or VTE) around the time of surgery. This guide reviews what the research says, why recommendations exist, and how to make decisions with your medical team. Keywords: birth control pill and surgery clot risk.
Any time you have surgery, factors such as immobility, inflammation and tissue damage can increase the chance of forming a clot in your veins. Adding estrogen from a combined oral contraceptive can further boost clot risk:
Put simply, surgery and the pill each carry a small clot risk. Together, they can temporarily raise that risk enough to warrant extra caution.
Most healthy, low-risk women who take a combined pill and have minor procedures (e.g., dental work under local anesthesia, colonoscopy without sedation) do not need to stop the pill. However, for higher-risk scenarios, guidelines suggest pausing estrogen:
Factors that increase clot risk further:
If you have any of these factors, your surgeon and prescribing clinician may recommend stopping the estrogen pill 4–6 weeks before surgery.
When you and your doctors decide that pausing estrogen makes sense, it’s important to time it correctly:
For short-acting pills, you simply stop at the end of a pack. For extended-cycle pills, finish the current active pills and wait 4–6 weeks before surgery. Your provider may suggest switching to a progestin-only method (mini-pill, injection, IUD) during this window to maintain contraception without added clot risk.
Stopping estrogen can raise the chance of pregnancy if you’re sexually active. Discuss backup methods:
Each has its own side effects and effectiveness profile. Your clinician can help choose the right bridge until you restart or switch methods post-op.
Even after stopping estrogen, surgeons and anesthesiologists use additional strategies to keep you safe:
These measures often reduce VTE risk by more than 50%.
There’s a real benefit to combined pills—regulating cycles, reducing cramps, protecting bone density, and managing acne. Stopping estrogen isn’t always easy:
Work with your prescriber to weigh the pros and cons. For many women, a short break before surgery is a reasonable compromise to lower clot risk without major lifestyle disruption.
Even with precautions, it’s wise to stay alert for clot symptoms, especially in the first 2-3 weeks after surgery:
If you notice any of these, seek immediate medical attention. You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Always discuss any plan to stop or switch birth control with your surgeon and prescribing doctor. This ensures you maintain both safety and effective contraception.
Speak to a doctor about anything that could be life-threatening or serious. A personalized evaluation will guide you through the safest approach for your upcoming surgery.
(References)
* Kontturi M, Sotaniemi E. Thromboembolism during estrogen therapy of prostatic cancer. Report on two cases. Scand J Urol Nephrol. 1971;5(2):108-10. doi: 10.3109/00365597109133587. PMID: 4255241.
* Jick SS, Vasilakis C, Jick H. Pregnancies and terminations after 1995 warning about third-generation oral contraceptives. Lancet. 1998 May 9;351(9113):1404-5. doi: 10.1016/S0140-6736(05)79443-5. PMID: 9593415.
* Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care. 2000 Dec;5(4):265-74. doi: 10.1080/13625180008500402. PMID: 11245554.
* Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ, British Society for Haematology Obstetric Haematology Group. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol. 2007 Nov;139(4):545-58. doi: 10.1111/j.1365-2141.2007.06826.x. Epub 2007 Oct 3. PMID: 17916101.
* Geirsson RT. The onward walk. Acta Obstet Gynecol Scand. 2012 Jul;91(7):763-4. doi: 10.1111/j.1600-0412.2012.01465.x. PMID: 22708735.
* Royer PA, Jones KP. Progestins for contraception: modern delivery systems and novel formulations. Clin Obstet Gynecol. 2014 Dec;57(4):644-58. doi: 10.1097/GRF.0000000000000072. PMID: 25314087.
* Cameron S. Venous thromboembolism and combined hormonal contraception: what are the implications for prescribing? BJOG. 2017 Sep;124(10):1500. doi: 10.1111/1471-0528.14663. Epub 2017 May 23. PMID: 28371111.
* Klok FA, Schreiber K, Stach K, Ageno W, Middeldorp S, Eichinger S, Delluc A, Blondon M, Ay C. Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey. Thromb Res. 2017 May;153:101-107. doi: 10.1016/j.thromres.2017.03.013. Epub 2017 Mar 20. PMID: 28376343.
* Middeldorp S, Iorio A. Oral contraceptive use is a provoking factor for venous thromboembolism. BMJ. 2017 Apr 27;357:j2073. doi: 10.1136/bmj.j2073. Epub 2017 Apr 27. PMID: 28450404.
* Raskin L, Didembourg M, Dogne JM, Locquet M, Creinin MD, Beaudart C, Douxfils J. Venous thromboembolism with combined oral contraceptives based on estrogen and progestin content: a disproportionality analysis of the United States Food and Drug Administration Adverse Event Reporting System database. Am J Obstet Gynecol. 2026 Jul;235(1):78-85. doi: 10.1016/j.ajog.2026.02.046. Epub 2026 Mar 4. PMID: 41791560.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.